Harbour BioMed Joins Stock Connect Following Profitability Milestone
Harbour BioMed shares are now eligible for trading via the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, granting mainland Chinese investors direct access to the biopharmaceutical firm. This transition follows the company’s recent market capitalization surge past HK$10 billion, signaling its entry into the ranks of mid-to-large-cap entities.
The inclusion reflects a period of financial stability for the firm, which reported US$122.5 million in revenue for the first half of 2026—a 20.9% year-over-year increase. With US$71.6 million in adjusted net profit, the company has now recorded seven consecutive profitable half-years. This performance provides the liquidity needed to advance a pipeline of nearly 30 drug candidates, including the lead asset batoclimab, currently undergoing Biologics License Application review.
Beyond internal development, the company has secured a global footprint through licensing agreements with firms like AstraZeneca, Otsuka Pharmaceutical, and Pfizer, with cumulative deal values exceeding US$13 billion. A core component of this strategy involves its Harbour Mice platform and the integration of AI-driven discovery, which enables complex antibody design. By joining the Stock Connect, Harbour BioMed expects to diversify its investor base and improve market visibility, further anchoring its position as a key player in the international biotechnology sector.
Comments (0)
No comments yet. Be the first!